PTX Pernix Therapeutics Holdings, I

4.42
-0.20  -4%
Previous Close 4.62
Open 4.66
Price To book 0.00
Market Cap 44.27M
Shares 10,015,000
Volume 155,886
Short Ratio 3.10
Av. Daily Volume 429,744

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approved May 15, 2015.
TREXIMET
Adolescent migraine patients

Latest News

  1. ETFs with exposure to Pernix Therapeutics Holdings, Inc. : June 13, 2017
  2. Edited Transcript of PTX earnings conference call or presentation 15-May-17 8:30pm GMT
  3. Pernix Therapeutics Holdings, Inc. :PTX-US: Earnings Analysis: Q1, 2017 By the Numbers : May 19, 2017
  4. ETFs with exposure to Pernix Therapeutics Holdings, Inc. : May 16, 2017
  5. Pernix Therapeutics Reports First Quarter 2017 Financial Results and Provides Business Update
  6. Investor Network: Pernix Therapeutics Holdings, Inc. to Host Earnings Call
  7. Pernix Therapeutics to Report First Quarter 2017 Financial Results on Monday, May 15
  8. Pernix Therapeutics Provides Update on Availability of Zohydro® ER with BeadTek™ 20mg Strength
  9. Rennova Health and Pernix Therapeutics Both Led In the Pharma Arena with Significant Share Price Jumps
  10. Platinex Inc.-Proposed Private Placement
  11. ETFs with exposure to Pernix Therapeutics Holdings, Inc. : April 7, 2017
  12. Pernix Therapeutics Holdings, Inc. :PTX-US: Earnings Analysis: Q4, 2016 By the Numbers : April 5, 2017
  13. Today's Research Reports on Biotech Stocks to Watch: Catalyst Biosciences and Pernix Therapeutics
  14. Edited Transcript of PTX earnings conference call or presentation 28-Mar-17 8:30pm GMT
  15. Pernix: An Investor's Rationale to Staying Long
  16. Biotech's Rise Shows No Sign of Slowing Dow in 2017: Today's Reports on Pernix Therapeutics and Brainstorm Cell Therapeutics